# PRIMORDIUM (NCT04557059)

> A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04557059
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Pharmaceutica N.V., Belgium
- Conditions: Prostatic Neoplasms
- Interventions: Radiotherapy; LHRHa; Apalutamide
- Enrollment: 691
- Primary outcome: Prostate specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Metastatic Progression-free Survival (ppMPFS)

## Commentary we found

- YouTube: 7
- Podcasts: 6
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=primordium-nct04557059

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04557059", "email": "<work email>"}; the inbox owner confirms by the emailed link.